Amino Acid Transporter System PET/CT Imaging in AATS-Related Diseases

Tianjin Medical University

Status

Enrolling

Conditions

Amino-Acid Transport Disorder

Glioma

Primary Hyperparathyroidism

Treatments

Diagnostic Test: 11C/18F-MET/FET

Study type

Observational

Funder types

Other

Identifiers

NCT07379463

TJMUGH-14

Details and patient eligibility

About

To evaluate the potential usefulness of 11C/18F-MET/FET positron emission tomography/ computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various amino acid transporter system (AATS)-related disease patients.

Full description

Subjects with various AATS-related disease (Primary Hyperparathyroidism, Glioma, et al) patients underwent 11C/18F-MET/FET PET/CT either for an initial assessment or for recurrence detection. Lesions uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 11C/18F-MET/FET were calculated.

Enrollment

500 estimated patients

Sex

All

Ages

18 to 90 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

adult patients (aged 18 years or order);
patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report);
patients who had scheduled AATS PET/CT scan;
patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion criteria

patients with non-malignant lesions;
patients with pregnancy;
the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.